LAS VEGAS, NV, March 29, 2023 (GLOBE NEWSWIRE) -- PSYC Corporation (OTC Pink Market: PSYC) (“PSYC”, “PSYC Corp” or the “Company”), parent company to Spotlight Media Corporation (“SMC” or the “wholly owned subsidiary”), a multimedia leader positioned at the intersection where all things psychedelics and cannabis converge, is pleased to announce that PSYC CEO, David Flores, will participate in the Penn Psychedelics Collaborative (the “PPC”) film screening event, “Psychedelics & the Road to Recovery,” which will feature a special screening of "Peace of Mind", a new documentary produced by ESPN highlighting the potential benefits of psychedelic-assisted therapy for traumatic brain injury (“TBI”) and mental health disorders, to be held at the Perelman School of Medicine on the University of Pennsylvania campus on Sunday, April 23rd.
Following the film screening, the PPC will host a panel discussion with experts in the fields of neurology, TBI research, psychedelic-assisted therapy, and policy moderated by David Flores. Panelists will discuss the potential benefits of psychedelics in the treatment of traumatic brain injury, pathology and recovery in humans, drug development and treatment strategies, the current state of research and regulatory policy, and ethical considerations of using psychedelics in a therapeutic setting.
The documentary, which will air nationally on ESPN on Saturday, April 22nd, explores the experiences of former NFL and NHL players, such as Riley Cote, who will be in attendance at the film screening, who suffered from TBI and mental health disorders and turned to psychedelic-assisted therapy, specifically with psilocybin, in hopes of improving their mental and physical wellbeing. Moreover, the film examines the promising results of psychedelic-assisted therapy and its potential as a viable treatment for these debilitating conditions.
This event is open to the public and will take place on Sunday, April 23rd, 2023, at the University of Pennsylvania’s Perelman School of Medicine's Clinical Research Building auditorium. Doors open at 2:00 pm and the event begins promptly at 2:30 pm. Attendees should register in advance through the Eventbrite link provided below.
As a moderator for the panel discussion, Mr. Flores will be representing PSYC’s Psychedelic Spotlight, a top 3 globally ranked psychedelic-focused multimedia platform.
“I’m truly honored to have this wonderful opportunity to represent PSYC and Psychedelic Spotlight as a moderator for what is certain to be a highly educational and information-packed panel discussion regarding the potential benefits of psychedelics in the treatment of TBI and other debilitating mental health conditions,” said Mr. Flores.
“Since launching Psychedelic Spotlight nearly 3 years ago, one of our primary objectives has been to be at the forefront of this exciting new paradigm shift involving psychedelic-assisted therapy. Events just like this offer PSYC unique opportunities to be visible leaders of this positive disruption to old, ineffective, inefficient, and overly expensive healthcare models and to foster new conversations without old stigmas. In my opinion, this is yet another demonstration of our commitment to further solidifying PSYC’s position as a news, information, and resource leader for this growing community of psychedelic-inspired healing.
We are incredibly grateful for our friends at The Spore Group for all of the fantastic work they did in helping to bring this event together alongside the Penn Psychedelics Collaborative, Wake, Reason for Hope, and the VA Center for Neurotrauma, Neurodegeneration and Restoration and look forward to hosting an inspirational event.”
"We hope this event will spark meaningful conversation and increase awareness of the early evidence that demonstrates how psychedelics can be used to treat TBI and related disorders on a physiological level,” said Mia Lowry, Director of Outreach for The Spore Group.
A second screening event will also be held on Wednesday April 26th at Cooper University Health Care. This event will also feature Riley Cote as a speaker along with experts in the field of neuromodulation therapies for mental health disorders and pain management.
Information and tickets for the Cooper University Health Care screening event may be found at the link below:
About PSYC Corporation (OTC Pink Market: PSYC)
PSYC Corporation (the “Company” or “PSYC”) is a forward-thinking multimedia leader for progressive and emerging market sectors such as medicinal psychedelics and cannabis.
Management’s assessment is that through the diversified collection of multimedia platforms the Company owns and operates, and most specifically through the news, information, and engaging content they each produce and publish respectively, PSYC has effectively positioned itself at the forefront of some of today’s most dynamic and opportunity-filled market sectors.
About Spotlight Media Corporation
Spotlight Media Corporation (“SMC”) (www.spotlightmediacorp.com) is a Nevada Corporation and is a privately held wholly owned subsidiary of PSYC that was incorporated on February 8, 2022.
SMC currently owns and operates Psychedelic Spotlight which, according to the Company, has emerged as a recognized industry-leading multimedia platform dedicated to covering the growing movement across society involving psychedelic-assisted healing. Additionally, SMC also operates Bonfire, a community-focused, consumer-facing platform being developed to effectively meet the demands linked to the expanding interest and curiosity across society related to the healing and therapeutic wonders of psychedelics and other plant based and holistic modalities.
SMC’s service-focused media platforms include Technical 420, On the Bids, and Mushroom Stocks which each serve publicly traded companies operating in the sectors of cannabis, mining and precious metals, and medicinal psychedelics and have become valuable informational resources for individuals following each of these respective market sectors.
Forward-Looking Statements Disclaimer:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors, including the effect of COVID-19 and the success of the current vaccine distribution, the adverse effect of the Omicron variant, that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are disclosed on the OTC Markets.com website and is not incorporated by reference into such reports.
Disclaimer: PSYC Corporation does not in any way encourage or condone the use, purchase, sale or transfer of any illegal substances, nor do we encourage or condone partaking in any unlawful activities. We support a harm reduction approach for the purpose of education and promoting individual and public safety. If you are choosing to use psychedelic substances, please do so responsibly.
Corporate Contact:
PSYC Corporation (PSYC)
www.psyccorporation.com
www.spotlightmediacorp.com
(702) 239-1919
info@psyccorporation.com
OTC PINK MARKET: PSYC
